7,324 Shares in CVS Health Corporation $CVS Acquired by TSG Advice Partners LLC

by · The Markets Daily

TSG Advice Partners LLC acquired a new stake in CVS Health Corporation (NYSE:CVS – Free Report) during the 3rd quarter, HoldingsChannel reports. The firm acquired 7,324 shares of the pharmacy operator’s stock, valued at approximately $628,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CVS. Elevation Wealth Partners LLC boosted its stake in shares of CVS Health by 41.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock valued at $37,000 after buying an additional 105 shares during the period. HBW Advisory Services LLC grew its holdings in shares of CVS Health by 3.5% during the 3rd quarter. HBW Advisory Services LLC now owns 3,408 shares of the pharmacy operator’s stock valued at $292,000 after acquiring an additional 115 shares in the last quarter. Apella Capital LLC increased its stake in shares of CVS Health by 1.7% in the second quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock worth $724,000 after acquiring an additional 117 shares during the last quarter. Wellington Altus USA Inc. raised its holdings in shares of CVS Health by 13.3% during the second quarter. Wellington Altus USA Inc. now owns 1,025 shares of the pharmacy operator’s stock worth $106,000 after acquiring an additional 120 shares in the last quarter. Finally, Childress Capital Advisors LLC raised its holdings in shares of CVS Health by 3.9% during the third quarter. Childress Capital Advisors LLC now owns 3,497 shares of the pharmacy operator’s stock worth $300,000 after acquiring an additional 131 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of NYSE:CVS opened at $88.54 on Tuesday. The business has a fifty day moving average of $91.13 and a 200-day moving average of $88.80. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68. The firm has a market cap of $113.24 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60.

CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities research analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd were paid a $0.6650 dividend. The ex-dividend date of this dividend was Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.0%. CVS Health’s payout ratio is currently 70.37%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Piper Sandler set a $112.00 price objective on CVS Health in a research report on Wednesday, September 9th. Leerink Partners dropped their target price on CVS Health from $119.00 to $112.00 and set an “outperform” rating on the stock in a research report on Monday, October 12th. Weiss Ratings downgraded shares of CVS Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 9th. Robert W. Baird set a $107.00 target price on CVS Health in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. raised their price target on CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Nineteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and an average price target of $109.64.

Read Our Latest Research Report on CVS

CVS Health Profile

(Free Report)

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.

Recommended Stories

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).